Live Breaking News & Updates on Johnson Innovative

Stay updated with breaking news from Johnson innovative. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with. ....

San Diego , United States , University Of San Diego , Phleger Harrison , Carmine Stengone , Latham Watkins , Hollis Eden Pharmaceuticals , Clifford Chance , University Of San Diego School Law , Contineum Therapeutics Inc , Tyra Biosciences Inc , University Of California , Contineum Therapeutics , John Healy , General Counsel , Chief Executive Officer , Corporate Secretary , Tyra Biosciences , San Diego School , Johnson Innovative ,

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Region Flamande , Soult Ukpyolsi , South Korea , United States , Republic Of Korea , Byoung Chul Cho , Henar Hevia , Craig Tendler , American Lung Association , Slate Development , Janssen Cilag International , American Society Of Clinical Oncology , European Medicines Agency Seeking Approval , Janssen Cilag International Nv Inc , Committee For Medicinal Products Human Use , National Cancer Institute , European Society For Medical Oncology , Exchange Commission , None Of Janssen Cilag International , European Medicines Agency , Yonsei University College Of Medicine , Global Medical Affairs , American Society For Clinical Oncology Annual Meeting , European Commission , Clinical Oncology , Annual Meeting ,

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody. ....

David Lee , None Of Cilag Holding , Janssen Research Development , Janssen Biotech Inc , Cilag Holding , Numab Therapeutics , Global Immunology Therapeutic Area Head , Johnson Innovative , Candice Long , Worldwide Vice President , Hart Scott Rodino Antitrust Improvements Act , Innovative Medicine , Janssen Research , Janssen Biotech , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Yellow Jersey Therapeutics , Kaken Pharmaceutical , Asia Pacific ,

J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal

By Denny Jacob

Johnson & Johnson entered into an agreement with Numab Therapeutics to acquire the global rights for bispecific antibody NM26 in an all-cash deal valued at $1.25 billion.

. ....

David Lee , Denny Jacob , Numab Therapeutics , Johnson Innovative , Dow Jones ,